Burixafor Hydrobromide

氢溴酸布利沙福

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameBurixafor Hydrobromide
Drug Alias NameBurixaforum布利沙福burixaforWembley SuffolkTG-0054 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsProstatic NeoplasmsMultiple MyelomaLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
Originator CompaniesTaiGen Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAdbiotech Co LtdGPCR Therapeutics IncExicure Inc
Inactive CompaniesTaiGen Biotechnology Co LtdTaigen Pharmaceutical R & D (Beijing) Co Ltd
Active IndicationsHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsProstatic NeoplasmsMultiple MyelomaLymphoma, Non-Hodgkin +[5] 

Other Information

ATC CodeN/A
Related LinksN/A